Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs

Objectives To evaluate the effect of QD or BID 0.02% netarsudil ophthalmic solution (Aerie Pharmaceuticals) on intraocular pressure (IOP) in normotensive dogs and to describe any adverse effects. Animals studied Normotensive Labrador retriever dogs were included in this study: 10 received netarsudil in one eye and artificial tears in the contralateral eye QD, and 10 received netarsudil in one eye and artificial tears in the contralateral eye BID. Procedures Intraocular pressure curves were acquired over a 3‐day acclimation period, 5‐day dosing period (QD or BID—10 dogs/group), and 3‐day recovery period. Toxicity was assessed daily using slit‐lamp biomicroscopy and the semiquantitative preclinical ocular toxicology scoring system. Results Once‐daily dosing did not lower IOP over the entire 5‐day dosing period (95% CI 0.1 to −0.9 mm Hg, P = .20) or on the last day of dosing (95% CI 0.4 to −0.9 mm Hg, P = .65). Twice‐daily dosing resulted in a statistically significant, but clinically unimportant, IOP reduction over the entire 5‐day dosing period (−0.6 mm Hg; 95% CI 0.05 to −1.1 mm Hg, P = .02) and on the last day of dosing (−0.9 mm Hg; 95% CI 0.2 to −1.5 mm Hg, P = .003). Adverse events were limited to transient mild‐to‐moderate conjunctival hyperemia during the dosing phase in eyes receiving netarsudil vs control (P